Real-world data from the SURPASS registries (pooled analysis, N = 3,200+ women) shows similar patterns
Studies show that adding a GLP-1 to insulin therapy can reduce insulin requirements by 20-50%, meaning your current dose may cause dangerously low blood sugar without adjustment
References to specific products, dosing schedules, or clinical protocols in this article are for informational and educational purposes only and do not constitute an endorsement of any specific treatment approach
Retatrutide (LY3437943) is a novel triple agonist peptide targeting the GCGR, GIPR, and GLP-1R
This triangulation between biopsy, NITs, and systemic cardiometabolic measures helps validate the biological plausibility of the treatment effect and supports the use of NITs in future biopsy-sparing strategies